---
title: "Understanding the Market | HAIXI PHARMA once rose over 12%, more than 30% higher than the offering price, with a dual-line layout of generic drugs and innovative drugs"
description: "HAIXI PHARMA once rose over 12%, reaching HKD 114.9, an increase of over 30% compared to the offering price of HKD 86.4. As of the time of writing, it has risen 9.2%, trading at HKD 111.6, with a tran"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262354975.md"
published_at: "2025-10-23T06:13:03.000Z"
---

# Understanding the Market | HAIXI PHARMA once rose over 12%, more than 30% higher than the offering price, with a dual-line layout of generic drugs and innovative drugs

> HAIXI PHARMA once rose over 12%, reaching HKD 114.9, an increase of over 30% compared to the offering price of HKD 86.4. As of the time of writing, it has risen 9.2%, trading at HKD 111.6, with a transaction volume of HKD 20.9312 million. It is reported that HAIXI PHARMA is a pharmaceutical company in the commercialization stage, integrating research and development, production, and sales capabilities, with a pipeline of innovative drugs under research. As of the disclosure date of the prospectus, HAIXI PHARMA has 15 approved generic drug products, covering multiple therapeutic areas, including the digestive system, cardiovascular system, endocrine system, and nervous system. The company has also established a pipeline of four innovative drugs under research, covering cancer, ophthalmology, and respiratory diseases. HAIXI PHARMA previously stated in its prospectus that it plans to actively explore opportunities for collaboration with multinational companies (MNCs) in the future to expand the company's international clinical research and commercialization capabilities

According to the Zhitong Finance APP, HAIXI PHARMA (02637) once rose over 12%, reaching HKD 114.9, an increase of over 30% compared to the offering price of HKD 86.4. As of the time of writing, it has risen by 9.2%, trading at HKD 111.6, with a transaction volume of HKD 20.9312 million.

It is reported that HAIXI PHARMA is a pharmaceutical company in the commercialization stage, integrating research and development, production, and sales capabilities, with a pipeline of innovative drugs under development. As of the disclosure date of the prospectus, HAIXI PHARMA has 15 approved generic drug products, covering multiple therapeutic areas, including the digestive system, cardiovascular system, endocrine system, and nervous system. The company has also established a pipeline of four innovative drugs under development, covering cancer, ophthalmology, and respiratory diseases. HAIXI PHARMA previously stated in its prospectus that it plans to actively explore opportunities for collaboration with multinational companies (MNCs) in the future to expand the company's international clinical research and commercialization capabilities

### Related Stocks

- [02637.HK - HAIXI PHARMA](https://longbridge.com/en/quote/02637.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Dramatic changes observed in one of universe's biggest stars | A star named WOH G64, located in the Large Magellanic Cloud, has been observed evolving from a red supergiant to a yello | [Link](https://longbridge.com/en/news/277297363.md) |
| Suzhou Ribo Life Science's Cholesterol Medicine to Begin Phase 3 Trial | Suzhou Ribo Life Science's Cholesterol Medicine to Begin Phase 3 Trial | [Link](https://longbridge.com/en/news/277401406.md) |
| Shanghai XNG Terminates HK$12 Million Share Placement | Shanghai XNG Terminates HK$12 Million Share Placement | [Link](https://longbridge.com/en/news/277392488.md) |
| Suzhou Ribo Advances PCSK9 siRNA Drug RBD7022 Into Phase III Trial in China | Suzhou Ribo Life Science Co., Ltd. has announced the advancement of its siRNA therapy, RBD7022, into Phase III clinical  | [Link](https://longbridge.com/en/news/277382303.md) |
| Chinese robotaxi firms halt Dubai operations amid Middle East conflict | Chinese robotaxi firms Baidu's Apollo Go and WeRide have suspended operations in Dubai due to escalating geopolitical te | [Link](https://longbridge.com/en/news/277352074.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.